Posters Modérés

 

Mardi 12 juin - 15h00 à 16h30

Zone jaune

  • PM1 - 001 - Venlafaxine : the baby ecstasy? About cases reported to addictovigilance centers - Basile CHRÉTIEN (Caen)
  • PM1 - 002 - Atypical antipsychotic misuse and adverse events: a review of the French Pharmacovigilance Database - Véronique PINZANI (Montpellier)
  • PM1 - 003 - Research chemicals benzodiazepines: data analysis of the French addictovigilance network and review of the literature - Helene PEYRIERE (Montpellier)
  • PM1 - 004 - Misuse of medicines containing codeine used for self-medication and community pharmacists - Amélie DAVELUY (Bordeaux)
  • PM1 - 005 - Trends in analgesics consumption in France, 2006-2015, and comparison of patterns across Europe - Karima HIDER MLYNARZ (Saint Denis)
  • PM1 - 006 - Assessment of diverted use of psychoactive drugs by adolescents and young adults in community pharmacies - Emilie JOUANJUS (Toulouse)
  • PM1 - 007 - Analgesic consumption in subjects with substance use disorder - Camille PONTÉ (Toulouse)

Zone orange

  • PM1 - 008 - Microscopic colitis and non-steroidal anti-inflammatory drugs. - Brahim AZZOUZ (Reims)
  • PM1 - 009 - Atypical Hemolytic Uremic Syndrome (aHUS) after short-term ketoprofen treatment: about 2 cases - Jean-Luc FAILLIE (Montpellier)
  • PM1 - 010 - Harm signal: 5 cases of serious painful musculoskeletal syndrome among 79 patients treated with teriflunomide - Laure PEYRO-SAINT-PAUL (Caen)
  • PM1 - 011 - Cardiovascular safety of methylphenidate in adult attention deficit hyperactivity disorder (ADHD): the Lille experience - Camille POTEY (Lille)
  • PM1 - 012 - Immunomodulatory imide drugs and progressive multifocal leukoencephalopathy: about 4 cases - Jean-Luc FAILLIE (Montpellier)
  • PM1 - 013 - Gaucher disease : French cohort of the 58 patients treated by eliglustat - Céline VERSTUYFT (Le Kremlin Bicetre)

Zone rose

  • PM1 - 014 - Nicorandil-induced ulcerations: A 10-year observational study of spontaneously reported cases to the French pharmacovigilance network. - Nadine PETITPAIN (Nancy)
  • PM1 - 015 - Drug-induced anaphylaxis in the French and Vietnamese pharmacovigilance databases 2010-2015 : a social pharmacological discussion - Khac-Dung NGUYEN (Toulouse)
  • PM1 - 016 - Evaluation of a "hybrid" e-learning approach based on peer-evaluation in the field of pharmacovigilance, drug-drug interactions and drug contraindications - Roland Fabrice LAWSON (Limoges)
  • PM1 - 017 - Paradoxical injunctions get along with quality insurance in pharmacovigilance - Sofia BERRIRI (Nice)
  • PM1 - 018 - Drug related deaths : retrospective analysis in a French universitary hospital - Marion LEPELLEY (Grenoble)
  • PM1 - 019 - Underreporting of adverse drug reactions (ADRs) from Skilled nursing homes (SNH): Survey in the Loire department to identify obstacles and suggest improvement measures. - Olivia THAO-THIEBAUT (Saint-Etienne)
  • PM1 - 020 - Comparison of Patients’ and Retail Pharmacies’ Adverse Drug Reaction Reports to a Regional Pharmacovigilance Regional Centre - Haleh BAGHERI (Toulouse)

Zone rouge

  • PM1 - 021 - Trends of sodium valproate prescriptions in children 0 to 14 years of age between 2010 and 2016: study from the French National Health Insurance Databasess - Elisabeth POLARD (Rennes)
  • PM1 - 022 - Drug reaction with eosinophilia and systemic symptoms in Pediatric Patients: a French nationwide study - Annie PIerre JONVILLE-BERA (Tours)
  • PM1 - 023 - Transversus abdominis plane block with levobupivacaine : first results of pharmacokinetics in pediatric patients - Olivier MATHIEU (Montpellier)
  • PM1 - 024 - Continuous infusion of vancomycin in critically ill children: do we achieve the target? - Sihem BENABOUD (Paris)
  • PM1 - 025 - Early Bayesian dose adjustment of vancomycin in children : a randomized controlled trial - Romain BERTHAUD (Paris)
  • PM1 - 026 - Trends in the use of analgesic opioids in pediatric patients: impact of safety recommendations - Nicolas AUTHIER (Clermont-Ferrand)
  • PM1 - 027 - Assessment of methotrexate serum concentrations in children with acute lymphoblastic leukemia - Souha BEN TEKAYA (Tunis)

Zone bleu clair

  • PM1 - 028 - Thromboembolic events in women exposed to hormonal contraception: regional comparison with data from the national pharmacovigilance survey carried out in 2012 and evaluation of prescription practices after new national guidelines. - Marie-Blanche VALNET RABIER (Besançon)
  • PM1 - 029 - The effectiveness of oral anticoagulants in the prevention of stroke in patients with non-valvular atrial fibrillation: results from the Stroke Prevention and Anticoagulants (SPA)study - Lamiae GRIMALDI-BENSOUDA (Paris)
  • PM1 - 030 - Comparative patterns of use of direct oral anticoagulants and vitamin K antagonists and risk of haemorrhage in real life - Lamiae GRIMALDI-BENSOUDA (Paris)
  • PM1 - 031 - A safety signal of venous thromboembolic events with the use of DPP-4 inhibitors: a pharmacovigilance disproportionality analysis - Amandine GOUVERNEUR (Bordeaux)
  • PM1 - 032 - Reports of Adverse events with levonorgestrel IUD Mirena in France before and after the 2017 media intense coverage - Amandine GOUVERNEUR (Bordeaux)
  • PM1 - 033 - P-glycoprotein (P-gp) antagonists may increase dabigatran plasma levels and bleeding occurrence in very elderly patients in usual conditions of care - Marjorie BERNIER (Nice)
  • PM1 - 034 - Retrospective analysis of seven years of heparin induced thrombocytopenia (HIT): a one center experience - Virginie FULDA (Paris)

Zone bleu foncé

  • PM1 - 035 - Intoxication with baclofen: is haemodialysis indicated? - Peggy GANDIA (Toulouse)
  • PM1 - 036 - Combination of Piperacillin-Tazobactam and Vancomycin with a risk of Acute Kidney Injury: a french pharmacovigilance survey - Judith COTTIN (Lyon)
  • PM1 - 037 - Factors associated with medium-low compliance in patients suffering from treatment resistant mood disorders - Caroline VICTORRI-VIGNEAU (Nantes)
  • PM1 - 038 - Drug Pain treatment and Fibromyalgia : Panacea or snake oil? - Alexanne ACHARD (Clermont-Ferrand)
  • PM1 - 039 - Hemolytic anemia and artemisinin derivatives: a case series - caroline JOYAU (Nantes)
  • PM1 - 040 - Effect of varenicline on smoking cessation in COPD patients recovering from exacerbation: a randomized trial - raphael LE MAO (Brest)
  • PM1 - 041 - Do patients in therapeutic failure, receiving mu opioid agonist for pain or addictive care, share the same characteristics? MUSIC -receptor mu and genetic- study - Caroline VICTORRI-VIGNEAU (Nantes)

Zone grise

  • PM1 - 042 - Trough dabrafenib plasma concentrations can predict occurrence of adverse effects requiring dose reduction in metastatic melanoma. - Marine ROUSSET (Bordeaux)
  • PM1 - 043 - A targeted genomic analysis uncovered a large spectrum of acquired resistance mechanisms to BRAF inhibitor therapy in metastatic melanoma patients - Baptiste LOUVEAU (Paris)
  • PM1 - 044 - Implementing routine pre-emptive DPD testing with adaptive dosing to secure 5-FU administration: Performance in digestive and head and neck cancer patients - Manon LAUNAY (Paris)
  • PM1 - 045 - Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders - Jean-Jacques TUDESQ (Montpellier)
  • PM1 - 046 - 5-fluorouracil and hyperammonemia - Julie LEBRUN (Montpellier)
  • PM1 - 047 - Real-life tolerance and plasma exposure assessment of lenvatinib in thyroid metastatic cancer patients - Lauriane GOLDWIRT (Paris)
  • PM1 - 048 - Biological monitoring of occupational exposure to 5-fluorouracil by urinary α-fluoro-β-alanine assay with a high sensitivity analytical method - Mathieu MOLIMARD (Bordeaux)

Zone violette

  • PM1 - 049 - Serotonin 2B receptor potentiates erythropoietin-induced mobilization of endothelial progenitor cells: contribution to hypoxic pulmonary arterial hypertension? - Estelle AYME-DIETRICH (Strasbourg)
  • PM1 - 050 - Effect of the iontophoresis of a prostacyclin analog on wound healing in a murine model of diabetes - Yann SAVINA (Grenoble)
  • PM1 - 051 - Endothelial cells exposed to uremic toxins secrete interleukin-8 which promotes vascular calcifications - Youssef BENNIS (Amiens)
  • PM1 - 052 - Encapsulation of prostacyclin analogs in lipid nanoparticles for the local treatment of skin ulcerations: formulation and pharmacokinetics. - Raphaël BOUVET (Grenoble)
  • PM1 - 053 - Effects of pharmacological inhibition of the hydrolase activity of soluble epoxide hydrolase in a murine model of pulmonary hypertension associated or not with cardiac insufficiency. - Matthieu LEUILLIER (Rouen)

Zone beige

  • PM1 - 054 - Endogenous metabolites-mediated communication between OAT1/OAT3 and OATP1B1 may explain the association between SLCO1B1 SNPs and methotrexate toxicity - chantal BARIN-LE GUELLEC (Tours)
  • PM1 - 055 - Simultaneous cocktail phenotyping of CYP450-mediated drug metabolism in patients with inappropriate response to psychotropic drugs - Xavier DECLÈVES (Paris)
  • PM1 - 056 - Comparison of validated Caco-2 and MDCKs in vitro cell models for drug transport studies - Elodie JACQUEROUX (Saint-Etienne)
  • PM1 - 057 - Evaluation of a strategy to enhance the brain distribution of erlotinib: a [11C]erlotinib PET imaging study in nonhuman primates - Nicolas TOURNIER (Orsay)
  • PM1 - 058 - Cirrhotic patients, especially those with neurological symptoms, display dramatically increased levels of several xenobiotics in plasma, a metabolomic study - Nicolas WEISS (Paris)
  • PM1 - 059 - How pharmacogenetics effects disappear over time : SLCO1B1 polymorphism and early discontinuation of statin therapy after acute myocardial infarction - Becquemont LAURENT (Le Kremlin-Bicêtre)

Zone marron

  • PM1 - 060 - ITPA activity: Relation to thiopurine metabolites and TPMT activity - Roselyne BOULIEU (Lyon)
  • PM1 - 061 - Liquid chromatography/ mass spectrometry and pharmacokinetic modelling as complementary tools for the personalization of infliximab treatment. - Benjamin NEMOZ (Grenoble)
  • PM1 - 062 - Dried blood spot for therapeutic drug monitoring of ciclosporin - Véronique LELONG-BOULOUARD (Caen)
  • PM1 - 063 - Development of a Population Pharmacokinetic model and a Bayesian Estimator for estimation of Everolimus Whole Blood and Intra-lymphocyte Exposure in Renal Transplant Recipients - Jean-Baptiste WOILLARD (Limoges)
  • PM1 - 064 - Interest of therapeutic drug monitoring of tacrolimus in bile matrix in liver transplant recipients: the STABILE study. - Camille TRON (Rennes)
  • PM1 - 065 - Clinical impact of reassessed tacrolimus starting dose according to CYP3A5 genotype in kidney transplant recipients - Chantal BARIN-LE GUELLEC (Tours)

Zone verte

  • PM1 - 066 - Impact of medication reconciliation on the sustainability of post-hospitalization prescriptions - Aurélie DAUMAS (Marseille)
  • PM1 - 067 - Prevalence of inappropriate drug prescription in patients with chronic kidney disease and the impact of equation used to estimate kidney function - Sophie LIABEUF (Amiens)
  • PM1 - 068 - Misuse of strong opioids in patients with cancer in the last year of life - Manuela RUETER (Toulouse)
  • PM1 - 069 - Nonagenarians presenting to the emergency department after falls-related drug use: characteristics and outcomes - Jacques BOUGET (Rennes)
  • PM1 - 070 - Prevalence and factors associated with medical drug purchase in the streets of Port-au-Prince, Haiti - Ydrif Léonard FRETT (Port-Au-Prince)
  • PM1 - 071 - Medication errors involving single dose pods before and after an information campaign - Farid KHELOUFI (Marseille)

 

Mercredi 13 juin - 09h30 à 11h00

Zone jaune

  • PM2 - 001 - Pharmacosurveillance of opioids analgesics : a pharmacoepidemiological study using doctor shopping indicator in French health Insurance database - Joelle MICALLEF (Marseille)
  • PM2 - 002 - Evaluation of possible addiction among migrant women consuming kaolin in metropolitan France: a pilot study - Caroline VICTORRI-VIGNEAU (Nantes)
  • PM2 - 003 - Opioid maintenance therapy in France: high-dosage buprenorphine still predominant despite a high increase in methadone use: results from the 2009-2015 UTOPIA study - Sandy MAUMUS-ROBERT (Bordeaux)
  • PM2 - 004 - Off-label use of oral morphine sulfate for opioid maintenance purpose in France: results from the 2009-2015 UTOPIA study - Sandy MAUMUS-ROBERT (Bordeaux)
  • PM2 - 005 - Nine years of Methadone post marketing surveillance from the French addictovigilance network data - Elisabeth FRAUGER (Marseille)
  • PM2 - 006 - interactions between buprenorphine and benzodiazepines promote prolonged opioid dependence - Antoine COQUEREL (Caen)
  • PM2 - 007 - Unintentional prescription opioid overdose-related hospitalizations in France: an emerging signal ? - Nicolas AUTHIER (Clermont-Ferrand)

Zone orange

  • PM2 - 008 - Pharmacokinetics of baclofen in alcoolic-dependent patients with cirrhosis - Xavier DECLÈVES (Paris)
  • PM2 - 009 - Baclofen and sleep apnoea syndrome: analysis of VigiBase® the WHO pharmacovigilance database - Bruno REVOL (Grenoble)
  • PM2 - 010 - Neuromuscular Blocking Agents induced anaphylaxis: the French pharmacovigilance experience from 2000 to 2012 - Nadine PETITPAIN (Nancy)
  • PM2 - 011 - TNF inhibitors and amyotrophic lateral sclerosis: a risk factor ? - Nadine PETITPAIN (Nancy)
  • PM2 - 012 - Neurological impairment in cirrhotic patients admitted to ICU: hepatic or drug-induced encephalopathy ? - Nicolas WEISS (Paris)
  • PM2 - 013 - Long-term antidepressant treatment and valvular heart disease? - Romain DE JORNA (Montpellier)

Zone rose

  • PM2 - 014 - Serious drug adverse reactions: A retrospective and descriptive study from the French regions of Bordeaux, Limoges, and Poitiers - Amandine GOUVERNEUR (Bordeaux)
  • PM2 - 015 - A week for patient safety: "All actors, all vigilant" - Anaïs GAIFFE (Besançon)
  • PM2 - 016 - Prescribing practices for the elderly in Residential Care homes for the Elderly (EHPAD): a pharmacological approach of the PAAPI (Elderly patients & Inappropriate Prescriptions) program - Haleh BAGHERI (Toulouse)
  • PM2 - 017 - Anticholinergic drug use and risk for age-related macular degeneration: a case–control study - Gauthier ALDEBERT (Montpellier)
  • PM2 - 018 - Psoriasis during angiotensin receptor blocker exposure : a case/non case study using the French Pharmacovigilance Database. - Brahim AZZOUZ (Reims)
  • PM2 - 019 - The era of pharmacosurveillance - Malak ABOU TAAM (Saint-Denis)
  • PM2 - 020 - Evaluation of online discussion forums as a complementary source of data for pharmacovigilance: the Vigi4MED project - Florelle BELLET (Saint-Etienne)

Zone rouge

  • PM2 - 021 - Pregnant women need more information on paracetamol: a survey in 480 expecting women - Julie VILLECOURT (Clermont-Fd)
  • PM2 - 022 - Medical care of pregnant women treated by sodium valproate : observational study from the french medico-administrative database from 2011 to 2016. - Adeline DEGREMONT (Rennes)
  • PM2 - 023 - Analysis of the new POMME cohort data: drug exposure in children from the first day of the intrauterine life until 6 years old - Justine BENEVENT (Toulouse)
  • PM2 - 024 - Single administration of amiodarone by intravenous route and breastfeeding - Lucie JAVOT (Nancy)
  • PM2 - 025 - Non-steroidal anti-inflammatory drugs (NSAIDs) prescriptions after the 6th month of pregnancy: impact of health authorities' advice - Mélanie ARAUJO (Toulouse)
  • PM2 - 026 - In utero drug exposure and hearing disorders in 2-year-old children: A case-control study using the EFEMERIS database - Isabelle LACROIX (Toulouse)
  • PM2 - 027 - Analysis of data on exposure to modafinil during pregnancy - Marion LEPELLEY (Grenoble)

Zone bleu clair

  • PM2 - 028 - Adverse drug reactions reported with antialdosterones to French Pharmacovigilance database - Sophie FEDRIZZI (Caen)
  • PM2 - 029 - Acute hypotensive and chronic treatments effects of Phyllanthus amarus (Euphorbiaceae) on blood pressure, cardiac and endothelial function in normotensive rabbits and DOCA-salt hypertensive rats - Alain N’guessan YAO (Abidjan)
  • PM2 - 030 - Comparative effectiveness of statins in cardiovascular secondary prevention - Jordan GUILLOT (Bordeaux)
  • PM2 - 031 - Association of the SLCO1B1 Haplotypes with myopathies under statins - Marwa AJMI (Sousse)
  • PM2 - 032 - US cholesterol guidelines do not fit French population - François GUEYFFIER (Lyon)
  • PM2 - 033 - Should cardiovascular deaths be frequent enough to observe a mortality decrease with statins ? A meta-regression approach. - François GUEYFFIER (Lyon)

Zone bleu foncé

  • PM2 - 034 - ISO 9001:2015 certification: Grenoble hospital’s clinical research and innovation delegation experience - Camille DUCKI (La Tronche)
  • PM2 - 035 - Cost-effectiveness of full versus targeted monitoring of randomized controlled trials - Claire FOUGEROU-LEURENT (Rennes)
  • PM2 - 036 - Impact of clinical trial requalification on safety management due to new French regulation - Clémence PONCET (Lyon)
  • PM2 - 037 - Overlapping network meta-analyses on the same topic - Florian NAUDET (Rennes)
  • PM2 - 038 - Interest of Data and Safety Monitoring Boards (DSMB) for category 1 clinical studies - Anthony FACILE (Lyon)

Zone grise

  • PM2 - 039 - Neuroprotective effect of Angiotensin II type 2 receptor stimulation in vincristine-induced sensory neuropathy - Claire DEMIOT (Limoges Cedex)
  • PM2 - 040 - Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in Polycythemia Vera: Two-Year Results from the First Prospective Randomized Controlled Trial - Lydia ROY (Créteil)
  • PM2 - 041 - Adverse effects of oral anticancer medications reported by patients from a clinical centre of oral therapies in Limoges: a descriptive analysis. - Hélène GÉNIAUX (Limoges)
  • PM2 - 042 - Tyrosine kinase inhibitors and digestive perforation: all responsible? - Camille POTEY (Lille)
  • PM2 - 043 - Combination of Dasatinib and Peg-Interferon alpha 2b in Chronic Phase Chronic Myeloid Leukemia first line: 24–Months results of a Phase II academic trial - Lydia ROY (Créteil)
  • PM2 - 044 - Evaluation of the Use of Apixaban in Prevention of Thromboembolic Disease in Patients With Myeloma Treated With iMiDs - Marylaure GAVARD (Grenoble)
  • PM2 - 045 - Post-marketing evaluation of medications in oncogeriatry: application to the treatment of metastatic colorectal cancer - Amandine GOUVERNEUR (Bordeaux)

Zone violette

  • PM2 - 046 - Reversible cerebral vasoconstriction syndrome (RCVS) and vasoactive drugs: analysis in the French pharmacovigilance database (FPD) and review of literature - Gwenaëlle VEYRAC (Nantes)
  • PM2 - 047 - Risk of stroke and myocardial infarction in users of vasoconstrictor drugs for ear, nose and throat related conditions - Lamiae GRIMALDI-BENSOUDA (Paris)
  • PM2 - 048 - Bladder cancers associated with gliflozin use: a case - non case analysis in the World Health Organization’s adverse drug reactions database - Sylvie DA SILVA (Montpellier)
  • PM2 - 049 - Drug-induced pulmonary arterial hypertension: a case-control study on VigiBase® - Marie-Laure LAROCHE (Limoges)
  • PM2 - 050 - Safety profile of sclerosing agents: an analysis from the world health organization pharmacovigilance database Vigibase®. - Charles KHOURI (Grenoble)

Zone beige

  • PM2 - 051 - Quantitative prediction of drug interaction with the DDI-predictor web-tool : a case study with the emergency contraceptive ulipristal - Claire LE CORVAISIER (Lyon)
  • PM2 - 052 - A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy - Christelle RODRIGUES (Paris)
  • PM2 - 053 - A pilot evaluation of the Population pharmacokinetics of vigabatrin enantiomers in infants and young children with epilepsy receiving a new soluble tablet form of vigabatrin. - Marwa OUNISSI (Paris)
  • PM2 - 054 - Influence of trough serum concentration on blood pressure rise in cancer patients treated with bevacizumab - Theodora BEJAN-ANGOULVANT (Tours)
  • PM2 - 055 - Forecasting drug-drug interactions for new drugs using the in vivo mechanistic static model: netupitant as a case study - Sylvain GOUTELLE (Lyon)
  • PM2 - 056 - Population pharmacokinetics of articaine with 1:200,000 epinephrine during third molar surgery and simulation of high-dose regimens - Yoann CAZAUBON (Reims)
  • PM2 - 057 - Valproate levels according in children to age - Rim CHARFI (Tunis)

Zone verte

  • PM2 - 058 - Model Based Meta-Analysis of Vancomycin Clearance during Renal Replacement Therapy: Application to Vancomycin pharmacokinetic during SLED in ICU patients - Edouard OLLIER (Saint Etienne)
  • PM2 - 059 - Darunavir unbound concentrations in plasma, not total concentration is the relevant concentration to predict darunavir efficacy in subject of different body mass index. - David METSU (Toulouse)
  • PM2 - 060 - Cefotaxime dosing regimen optimization in critically ill children - Sihem BENABOUD (Paris)
  • PM2 - 061 - Achievement of vancomycin AUC targets: a study in elderly patients - Vincent LECLERC (Lyon)
  • PM2 - 062 - Pharmacokinetics of ofloxacin in osteo-articular infected patients: should we consider therapeutic drug monitoring? - Florian LEMAITRE (Rennes)

 

 
 

Copyright © key4events - All rights reserved